Analyzing InMode (INMD) & The Competition

InMode (NASDAQ:INMD) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare InMode to related companies based on the strength of its risk, dividends, valuation, profitability, analyst recommendations, institutional ownership and earnings.

Profitability

This table compares InMode and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMode	19.94%	11.52%	10.16%
InMode Competitors	-300.62%	-179.55%	-22.71%

Valuation & Earnings

This table compares InMode and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InMode	$370.49 million	$93.83 million	10.79
InMode Competitors	$1.89 billion	$136.85 million	5.96

InMode’s rivals have higher revenue and earnings than InMode. InMode is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

68.0% of InMode shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

InMode has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, InMode’s rivals have a beta of 5.49, suggesting that their average share price is 449% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for InMode and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1	3	1	0	2.00
InMode Competitors	4302	10596	18377	837	2.46

InMode presently has a consensus price target of $16.33, indicating a potential upside of 23.08%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.33%. Given InMode’s higher possible upside, research analysts plainly believe InMode is more favorable than its rivals.

Summary

InMode rivals beat InMode on 7 of the 13 factors compared.

InMode Company Profile

InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.